Seattle Genetics to hold an investor and analyst event
Management discusses the Phase 3 ECHELON-2 Trial, as well as other key data presented at the ASH Annual Meeting, at an Investor and Analyst Event being held in San Diego, CA on December 3 at 11:15 pm.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.